TEVA Q4 2020 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$37B

Q4 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.5B-0.3% YoY

Gross Profit

$2.0B46.0% margin

Operating Income

$406M9.1% margin

Net Income

$150M3.4% margin

EPS (Diluted)

$0.14

QoQ Revenue Growth

+11.9%

Cash Flow

Operating Cash Flow

$331M

Free Cash Flow

$155M

Stock-Based Comp.

$38M

Balance Sheet

Total Assets

$50.6B

Total Liabilities

$39.6B

Stockholders' Equity

$10.0B

Cash & Equivalents

$2.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.5B	$4.5B	-0.3%
Gross Profit	$2.0B	$2.0B	+4.6%
Operating Income	$406M	$148M	+174.3%
Net Income	$150M	$109M	+37.6%

Revenue Segments

Product

$3.9B89%

Distribution Service

$330M7%

Product and Service, Other

$138M3%

License

$39M1%

Geographic Segments

North America Segment

$2.3B56%

Europe Segment

$1.2B30%

International Markets

$572M14%